| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2002 | EP1173223A2 Conjugates as therapies for cancers and prostate diseases |
| 01/23/2002 | EP1173222A2 Conjugate having a cleavable linkage for use in a liposome |
| 01/23/2002 | EP1173220A2 Targeting of infectious agents bearing host cell proteins |
| 01/23/2002 | EP1173219A1 Non-aqueous liquid shampoo composition |
| 01/23/2002 | EP1173218A1 Compositions for treatment of disorders of the oesophagus |
| 01/23/2002 | EP1173217A2 Enhanced delivery of nucleic acid-based drugs |
| 01/23/2002 | EP1173216A1 Pharmaceutical formulations |
| 01/23/2002 | EP1173214A2 Medicinal substance utilization for preventing nitrate tolerance |
| 01/23/2002 | EP1173213A1 Compositions containing benzimidazolones and progestogens |
| 01/23/2002 | EP1173212A1 Contraceptive compositions contaning indolone derivatives and progestational agents |
| 01/23/2002 | EP1173211A1 Contraceptive compositions containing 3,3-substituted indoline derivatives and uses thereof |
| 01/23/2002 | EP1173210A1 Contraceptive compositions containing antiprogestinic and progestinic |
| 01/23/2002 | EP1173209A1 Contraceptive compositions containing 2,1-benzisothiazoline 2,2-dioxides and progestationals |
| 01/23/2002 | EP1173208A2 Contraceptive compositions containing cyclic urea and amide derivatives |
| 01/23/2002 | EP1173206A1 Contraceptive compositions containing quinazolinone and benzoxazine derivatives |
| 01/23/2002 | EP1173205A1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| 01/23/2002 | EP1173188A2 Pharmaceutical composition comprising an inositol and a metal ion for improving insulin sensitivity and glucose metabolism |
| 01/23/2002 | EP1173187A2 Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 01/23/2002 | EP1173186A1 Use of tagatose to enhance key blood factors |
| 01/23/2002 | EP1173185A1 Increased fertility and improved fetal development drug |
| 01/23/2002 | EP1173183A2 Use of compounds with a nitrogen-oxygen heterocycle |
| 01/23/2002 | EP1173182A2 Use of estrone derivatives as antitumour agents |
| 01/23/2002 | EP1173181A2 Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction |
| 01/23/2002 | EP1173180A1 Camptothecin analogs and methods of preparation thereof |
| 01/23/2002 | EP1173179A2 Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
| 01/23/2002 | EP1173178A1 Apomorphine and sildenafil composition |
| 01/23/2002 | EP1173177A1 Use of macrolide compounds for the treatment of dry eye |
| 01/23/2002 | EP1173176A1 Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity |
| 01/23/2002 | EP1173175A1 A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping |
| 01/23/2002 | EP1173174A1 Methods for treatment of sickle cell anemia |
| 01/23/2002 | EP1173173A1 Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives |
| 01/23/2002 | EP1173172A1 Synergistic effects of amlodipine and atorvastatin |
| 01/23/2002 | EP1173171A1 Novel anticoagulant injectable composition |
| 01/23/2002 | EP1173170A1 Pyrrolidine modulators of chemokine receptor activity |
| 01/23/2002 | EP1173169A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 01/23/2002 | EP1173168A2 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 01/23/2002 | EP1173167A1 Treatment of female arousal disorder |
| 01/23/2002 | EP1173166A1 The use of alpha lipoic acid in the antimetastatic treatment |
| 01/23/2002 | EP1173165A1 Cardiovascular and bone treatment using isoflavones |
| 01/23/2002 | EP1173164A2 Estrogen receptor-beta ligands |
| 01/23/2002 | EP1173163A1 Pharmaceutical compositions of tetrac and methods of use thereof |
| 01/23/2002 | EP1173162A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/23/2002 | EP1173161A2 Glucamine compounds for treating hepatitis virus infections |
| 01/23/2002 | EP1173160A1 (e)-styryl sulfone anticancer agents |
| 01/23/2002 | EP1173159A1 Composition and method useful for treating colic |
| 01/23/2002 | EP1173158A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood |
| 01/23/2002 | EP1173155A1 Gum pad for delivery of medication to mucosal tissues |
| 01/23/2002 | EP1173153A1 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants |
| 01/23/2002 | EP1173152A2 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers |
| 01/23/2002 | EP1173149A1 Cosmetic and/or dietetic composition comprising a mixture of lycopene and olive leaf extract |
| 01/23/2002 | EP1173148A1 Method of improving the aesthetic appearance of epithelia |
| 01/23/2002 | EP1173144A1 Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents |
| 01/23/2002 | EP1173061A1 Compositions and methods for treatment of hyperproliferative diseases |
| 01/23/2002 | EP1135395A4 Crystalline salts of a carbapenem antibiotic |
| 01/23/2002 | EP1100444A4 Topical anionic salicylate for disorders of the skin |
| 01/23/2002 | EP1094802B1 Pharmaceutical composition for injection based on paracetamol |
| 01/23/2002 | EP1090028B1 Unsaturated 14,15-cyclopropanoandrostanes, method for the production thereof and pharmaceutical preparations containing said compounds |
| 01/23/2002 | EP1025100B1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
| 01/23/2002 | EP1023055B1 Inhibition of crystallization in transdermal devices |
| 01/23/2002 | EP0980254B1 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity |
| 01/23/2002 | EP0904269B1 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| 01/23/2002 | EP0902789B1 Androstene derivatives |
| 01/23/2002 | EP0884947A4 Dna vaccination for induction of suppressive t cell response |
| 01/23/2002 | EP0877091B1 Antifungal substances be-49385 and process for producing the same |
| 01/23/2002 | EP0865286B1 Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders |
| 01/23/2002 | EP0863887B1 Intermediary compounds for the hemisynthesis of taxanes and preparation processes therefor |
| 01/23/2002 | EP0854711B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 01/23/2002 | EP0846693B1 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same |
| 01/23/2002 | EP0841898B1 Topical compositions having improved skin feel |
| 01/23/2002 | EP0840621B1 Hormone patch |
| 01/23/2002 | EP0839046B1 Tnf receptor and steroid hormone dhea in a combined therapy |
| 01/23/2002 | EP0833826B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease |
| 01/23/2002 | EP0813539A4 Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| 01/23/2002 | EP0813411B1 Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein |
| 01/23/2002 | EP0752850B1 Pharmaceutical formulation |
| 01/23/2002 | EP0739903B1 Carbamoylmethylurea derivative |
| 01/23/2002 | EP0726771B1 Desferrioxamine oral delivery system |
| 01/23/2002 | EP0724586B1 Process for preparing n-(2,6-dichloro-3-methylphenyl)-5-7-dihalo[1,2,4]triazolo[1,5a]pyrimidine-2-sulfonamide by cyclization and halo-dehydroxylation |
| 01/23/2002 | EP0711292B1 Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| 01/23/2002 | EP0696205B1 Use of neuro-derived fetal cell lines for transplantation therapy |
| 01/23/2002 | EP0687265B1 Heterocyclic compounds and their preparation and use |
| 01/23/2002 | CN1332849A Methods and compositions to lower plasma cholesterol levels |
| 01/23/2002 | CN1332847A Substance containing shiitake mushroom hypha extract for soreening lak activity and method for screening lak activity by using the same |
| 01/23/2002 | CN1332801A Connective tissue growth factor (CTGF) and methods of use |
| 01/23/2002 | CN1332799A Cancer cell vaccine |
| 01/23/2002 | CN1332748A Isolated nucleic acid molecules which encodt T cell inducible factors (TIFs), proteins encoded, and uses thereof |
| 01/23/2002 | CN1332747A 2'-fluoronucleosides |
| 01/23/2002 | CN1332746A Novel derivatives from class of oleandomycin |
| 01/23/2002 | CN1332745A New compounds for treatment of cancer |
| 01/23/2002 | CN1332744A Tricyclic delta 3-piperidines as alpha 2-antagonists |
| 01/23/2002 | CN1332743A Cell adhesion-inhibiting antinflammatory compounds |
| 01/23/2002 | CN1332742A Epothilone derivatives and their use as antitumor agents |
| 01/23/2002 | CN1332741A Pyrazolopyridine derivatives as selective COX-2 inhibitors |
| 01/23/2002 | CN1332740A 5HT antagonists for antidepressant therapy |
| 01/23/2002 | CN1332737A Thrombin inhibitors |
| 01/23/2002 | CN1332734A Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity |
| 01/23/2002 | CN1332731A Substituted benzimidazoles and their prep. and use |
| 01/23/2002 | CN1332729A 4-oxo-1,4-dihybro-3-quinolinecarboxamides as antiviral agents |
| 01/23/2002 | CN1332727A 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| 01/23/2002 | CN1332725A Thiourea inhibitors of herpes viruses |